nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftriaxone—SLC22A11—Methotrexate—muscle cancer	0.301	0.429	CbGbCtD
Ceftriaxone—SLC22A8—Methotrexate—muscle cancer	0.175	0.249	CbGbCtD
Ceftriaxone—SLC22A6—Methotrexate—muscle cancer	0.122	0.174	CbGbCtD
Ceftriaxone—ALB—Methotrexate—muscle cancer	0.104	0.148	CbGbCtD
Ceftriaxone—Alveolitis allergic—Methotrexate—muscle cancer	0.00649	0.0223	CcSEcCtD
Ceftriaxone—Induration—Etoposide—muscle cancer	0.00632	0.0217	CcSEcCtD
Ceftriaxone—Coagulopathy—Dactinomycin—muscle cancer	0.00502	0.0173	CcSEcCtD
Ceftriaxone—Secondary infection—Doxorubicin—muscle cancer	0.00499	0.0172	CcSEcCtD
Ceftriaxone—Nephropathy toxic—Etoposide—muscle cancer	0.00492	0.0169	CcSEcCtD
Ceftriaxone—Warmth—Doxorubicin—muscle cancer	0.00461	0.0159	CcSEcCtD
Ceftriaxone—Haematocrit decreased—Methotrexate—muscle cancer	0.00455	0.0156	CcSEcCtD
Ceftriaxone—Drug interaction—Vincristine—muscle cancer	0.00376	0.0129	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Dactinomycin—muscle cancer	0.00367	0.0126	CcSEcCtD
Ceftriaxone—Phlebitis—Dactinomycin—muscle cancer	0.00329	0.0113	CcSEcCtD
Ceftriaxone—Lymphopenia—Doxorubicin—muscle cancer	0.00287	0.00985	CcSEcCtD
Ceftriaxone—Lactic dehydrogenase activity increased—Doxorubicin—muscle cancer	0.00287	0.00985	CcSEcCtD
Ceftriaxone—Candida infection—Etoposide—muscle cancer	0.0027	0.00928	CcSEcCtD
Ceftriaxone—Local reaction—Doxorubicin—muscle cancer	0.00265	0.00911	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00255	0.00878	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Dactinomycin—muscle cancer	0.00255	0.00878	CcSEcCtD
Ceftriaxone—Blood lactate dehydrogenase increased—Doxorubicin—muscle cancer	0.00252	0.00868	CcSEcCtD
Ceftriaxone—Serum creatinine increased—Doxorubicin—muscle cancer	0.00238	0.0082	CcSEcCtD
Ceftriaxone—Ataxia—Vincristine—muscle cancer	0.00238	0.00819	CcSEcCtD
Ceftriaxone—Phlebitis—Etoposide—muscle cancer	0.00238	0.00819	CcSEcCtD
Ceftriaxone—Thrombocytosis—Doxorubicin—muscle cancer	0.00236	0.00811	CcSEcCtD
Ceftriaxone—Neutropenia—Dactinomycin—muscle cancer	0.00229	0.00788	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00228	0.00784	CcSEcCtD
Ceftriaxone—Fungal infection—Methotrexate—muscle cancer	0.00219	0.00754	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Dactinomycin—muscle cancer	0.00217	0.00745	CcSEcCtD
Ceftriaxone—Stomatitis—Dactinomycin—muscle cancer	0.00213	0.00732	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Etoposide—muscle cancer	0.00212	0.00729	CcSEcCtD
Ceftriaxone—Neutropenia—Vincristine—muscle cancer	0.00205	0.00704	CcSEcCtD
Ceftriaxone—Agranulocytosis—Dactinomycin—muscle cancer	0.00204	0.00701	CcSEcCtD
Ceftriaxone—Dermatitis atopic—Doxorubicin—muscle cancer	0.00198	0.00681	CcSEcCtD
Ceftriaxone—Proteinuria—Methotrexate—muscle cancer	0.00193	0.00663	CcSEcCtD
Ceftriaxone—Stomatitis—Vincristine—muscle cancer	0.0019	0.00654	CcSEcCtD
Ceftriaxone—Protein urine present—Methotrexate—muscle cancer	0.0019	0.00654	CcSEcCtD
Ceftriaxone—Fungal infection—Doxorubicin—muscle cancer	0.0019	0.00653	CcSEcCtD
Ceftriaxone—Feeling hot—Doxorubicin—muscle cancer	0.00187	0.00642	CcSEcCtD
Ceftriaxone—Erythema multiforme—Dactinomycin—muscle cancer	0.00186	0.00638	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Etoposide—muscle cancer	0.00185	0.00635	CcSEcCtD
Ceftriaxone—Glossitis—Methotrexate—muscle cancer	0.00184	0.00632	CcSEcCtD
Ceftriaxone—Oliguria—Methotrexate—muscle cancer	0.00184	0.00632	CcSEcCtD
Ceftriaxone—Flushing—Dactinomycin—muscle cancer	0.00182	0.00626	CcSEcCtD
Ceftriaxone—Glycosuria—Doxorubicin—muscle cancer	0.00181	0.00622	CcSEcCtD
Ceftriaxone—Chills—Dactinomycin—muscle cancer	0.00176	0.00605	CcSEcCtD
Ceftriaxone—Bronchospasm—Etoposide—muscle cancer	0.00174	0.006	CcSEcCtD
Ceftriaxone—Sweating increased—Etoposide—muscle cancer	0.00173	0.00594	CcSEcCtD
Ceftriaxone—Vaginal inflammation—Methotrexate—muscle cancer	0.00169	0.00582	CcSEcCtD
Ceftriaxone—Neutropenia—Etoposide—muscle cancer	0.00166	0.0057	CcSEcCtD
Ceftriaxone—Vaginal infection—Methotrexate—muscle cancer	0.0016	0.0055	CcSEcCtD
Ceftriaxone—Oliguria—Doxorubicin—muscle cancer	0.00159	0.00547	CcSEcCtD
Ceftriaxone—Glossitis—Doxorubicin—muscle cancer	0.00159	0.00547	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Methotrexate—muscle cancer	0.00159	0.00547	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Dactinomycin—muscle cancer	0.00158	0.00545	CcSEcCtD
Ceftriaxone—Anaemia—Dactinomycin—muscle cancer	0.00158	0.00543	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.00157	0.00539	CcSEcCtD
Ceftriaxone—Renal failure—Etoposide—muscle cancer	0.00155	0.00535	CcSEcCtD
Ceftriaxone—Stomatitis—Etoposide—muscle cancer	0.00154	0.0053	CcSEcCtD
Ceftriaxone—Jaundice—Etoposide—muscle cancer	0.00154	0.0053	CcSEcCtD
Ceftriaxone—Malaise—Dactinomycin—muscle cancer	0.00154	0.0053	CcSEcCtD
Ceftriaxone—Leukopenia—Dactinomycin—muscle cancer	0.00153	0.00526	CcSEcCtD
Ceftriaxone—Agranulocytosis—Etoposide—muscle cancer	0.00148	0.00507	CcSEcCtD
Ceftriaxone—Vaginal inflammation—Doxorubicin—muscle cancer	0.00147	0.00504	CcSEcCtD
Ceftriaxone—Discomfort—Dactinomycin—muscle cancer	0.00144	0.00494	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Methotrexate—muscle cancer	0.00142	0.00488	CcSEcCtD
Ceftriaxone—Anaemia—Vincristine—muscle cancer	0.00141	0.00485	CcSEcCtD
Ceftriaxone—Colitis—Doxorubicin—muscle cancer	0.00141	0.00484	CcSEcCtD
Ceftriaxone—Agitation—Vincristine—muscle cancer	0.0014	0.00482	CcSEcCtD
Ceftriaxone—Candida infection—Doxorubicin—muscle cancer	0.0014	0.00481	CcSEcCtD
Ceftriaxone—Oedema—Dactinomycin—muscle cancer	0.00139	0.00479	CcSEcCtD
Ceftriaxone—Infection—Dactinomycin—muscle cancer	0.00138	0.00476	CcSEcCtD
Ceftriaxone—Vaginal infection—Doxorubicin—muscle cancer	0.00138	0.00476	CcSEcCtD
Ceftriaxone—Aplastic anaemia—Doxorubicin—muscle cancer	0.00138	0.00473	CcSEcCtD
Ceftriaxone—Leukopenia—Vincristine—muscle cancer	0.00137	0.0047	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Dactinomycin—muscle cancer	0.00136	0.00469	CcSEcCtD
Ceftriaxone—Erythema multiforme—Etoposide—muscle cancer	0.00134	0.00462	CcSEcCtD
Ceftriaxone—Convulsion—Vincristine—muscle cancer	0.00132	0.00455	CcSEcCtD
Ceftriaxone—Flushing—Etoposide—muscle cancer	0.00132	0.00453	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Methotrexate—muscle cancer	0.0013	0.00448	CcSEcCtD
Ceftriaxone—Hypertonia—Doxorubicin—muscle cancer	0.00129	0.00442	CcSEcCtD
Ceftriaxone—Chills—Etoposide—muscle cancer	0.00127	0.00438	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Methotrexate—muscle cancer	0.00127	0.00437	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Vincristine—muscle cancer	0.00125	0.00428	CcSEcCtD
Ceftriaxone—Oedema—Vincristine—muscle cancer	0.00125	0.00428	CcSEcCtD
Ceftriaxone—Infection—Vincristine—muscle cancer	0.00124	0.00425	CcSEcCtD
Ceftriaxone—Phlebitis—Doxorubicin—muscle cancer	0.00124	0.00425	CcSEcCtD
Ceftriaxone—Thrombophlebitis—Doxorubicin—muscle cancer	0.00123	0.00423	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Vincristine—muscle cancer	0.00122	0.00419	CcSEcCtD
Ceftriaxone—Hepatic function abnormal—Doxorubicin—muscle cancer	0.00122	0.00419	CcSEcCtD
Ceftriaxone—Dysgeusia—Etoposide—muscle cancer	0.00121	0.00416	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Vincristine—muscle cancer	0.0012	0.00414	CcSEcCtD
Ceftriaxone—Pain—Dactinomycin—muscle cancer	0.00119	0.0041	CcSEcCtD
Ceftriaxone—Ataxia—Methotrexate—muscle cancer	0.00116	0.00397	CcSEcCtD
Ceftriaxone—Feeling abnormal—Dactinomycin—muscle cancer	0.00115	0.00395	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Etoposide—muscle cancer	0.00115	0.00394	CcSEcCtD
Ceftriaxone—Anaemia—Etoposide—muscle cancer	0.00114	0.00393	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Dactinomycin—muscle cancer	0.00114	0.00392	CcSEcCtD
Ceftriaxone—Dermatitis exfoliative—Doxorubicin—muscle cancer	0.00113	0.00388	CcSEcCtD
Ceftriaxone—Renal impairment—Doxorubicin—muscle cancer	0.00112	0.00385	CcSEcCtD
Ceftriaxone—Paraesthesia—Vincristine—muscle cancer	0.00112	0.00384	CcSEcCtD
Ceftriaxone—Malaise—Etoposide—muscle cancer	0.00111	0.00383	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00111	0.00381	CcSEcCtD
Ceftriaxone—Leukopenia—Etoposide—muscle cancer	0.00111	0.0038	CcSEcCtD
Ceftriaxone—Abdominal pain—Dactinomycin—muscle cancer	0.0011	0.00379	CcSEcCtD
Ceftriaxone—Body temperature increased—Dactinomycin—muscle cancer	0.0011	0.00379	CcSEcCtD
Ceftriaxone—Anaphylactoid reaction—Doxorubicin—muscle cancer	0.0011	0.00378	CcSEcCtD
Ceftriaxone—Convulsion—Etoposide—muscle cancer	0.00107	0.00368	CcSEcCtD
Ceftriaxone—Pain—Vincristine—muscle cancer	0.00106	0.00366	CcSEcCtD
Ceftriaxone—Eosinophilia—Methotrexate—muscle cancer	0.00105	0.00362	CcSEcCtD
Ceftriaxone—Pancreatitis—Methotrexate—muscle cancer	0.00104	0.00358	CcSEcCtD
Ceftriaxone—Discomfort—Etoposide—muscle cancer	0.00104	0.00357	CcSEcCtD
Ceftriaxone—Hypersensitivity—Dactinomycin—muscle cancer	0.00103	0.00353	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Vincristine—muscle cancer	0.00102	0.0035	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Etoposide—muscle cancer	0.00101	0.00347	CcSEcCtD
Ceftriaxone—Infection—Etoposide—muscle cancer	0.001	0.00345	CcSEcCtD
Ceftriaxone—Ataxia—Doxorubicin—muscle cancer	0.001	0.00344	CcSEcCtD
Ceftriaxone—Blood creatinine increased—Doxorubicin—muscle cancer	0.000997	0.00343	CcSEcCtD
Ceftriaxone—Neutropenia—Methotrexate—muscle cancer	0.000994	0.00342	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Etoposide—muscle cancer	0.000988	0.0034	CcSEcCtD
Ceftriaxone—Abdominal pain—Vincristine—muscle cancer	0.000984	0.00338	CcSEcCtD
Ceftriaxone—Body temperature increased—Vincristine—muscle cancer	0.000984	0.00338	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Etoposide—muscle cancer	0.000975	0.00335	CcSEcCtD
Ceftriaxone—Abdominal pain upper—Doxorubicin—muscle cancer	0.000972	0.00334	CcSEcCtD
Ceftriaxone—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000959	0.0033	CcSEcCtD
Ceftriaxone—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000959	0.0033	CcSEcCtD
Ceftriaxone—Diarrhoea—Dactinomycin—muscle cancer	0.000954	0.00328	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000939	0.00323	CcSEcCtD
Ceftriaxone—Renal failure—Methotrexate—muscle cancer	0.000931	0.0032	CcSEcCtD
Ceftriaxone—Stomatitis—Methotrexate—muscle cancer	0.000924	0.00318	CcSEcCtD
Ceftriaxone—Hypersensitivity—Vincristine—muscle cancer	0.000918	0.00315	CcSEcCtD
Ceftriaxone—Eosinophilia—Doxorubicin—muscle cancer	0.000911	0.00313	CcSEcCtD
Ceftriaxone—Paraesthesia—Etoposide—muscle cancer	0.000906	0.00311	CcSEcCtD
Ceftriaxone—Haematuria—Methotrexate—muscle cancer	0.000903	0.00311	CcSEcCtD
Ceftriaxone—Pancreatitis—Doxorubicin—muscle cancer	0.000902	0.0031	CcSEcCtD
Ceftriaxone—Epistaxis—Methotrexate—muscle cancer	0.000894	0.00307	CcSEcCtD
Ceftriaxone—Vomiting—Dactinomycin—muscle cancer	0.000886	0.00305	CcSEcCtD
Ceftriaxone—Agranulocytosis—Methotrexate—muscle cancer	0.000884	0.00304	CcSEcCtD
Ceftriaxone—Rash—Dactinomycin—muscle cancer	0.000879	0.00302	CcSEcCtD
Ceftriaxone—Pain—Etoposide—muscle cancer	0.000863	0.00297	CcSEcCtD
Ceftriaxone—Neutropenia—Doxorubicin—muscle cancer	0.00086	0.00296	CcSEcCtD
Ceftriaxone—Haemoglobin—Methotrexate—muscle cancer	0.000855	0.00294	CcSEcCtD
Ceftriaxone—Diarrhoea—Vincristine—muscle cancer	0.000852	0.00293	CcSEcCtD
Ceftriaxone—Haemorrhage—Methotrexate—muscle cancer	0.000851	0.00292	CcSEcCtD
Ceftriaxone—Feeling abnormal—Etoposide—muscle cancer	0.000831	0.00286	CcSEcCtD
Ceftriaxone—Nausea—Dactinomycin—muscle cancer	0.000828	0.00285	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Etoposide—muscle cancer	0.000825	0.00284	CcSEcCtD
Ceftriaxone—Dizziness—Vincristine—muscle cancer	0.000824	0.00283	CcSEcCtD
Ceftriaxone—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000813	0.0028	CcSEcCtD
Ceftriaxone—Renal failure—Doxorubicin—muscle cancer	0.000806	0.00277	CcSEcCtD
Ceftriaxone—Erythema multiforme—Methotrexate—muscle cancer	0.000804	0.00276	CcSEcCtD
Ceftriaxone—Urticaria—Etoposide—muscle cancer	0.000801	0.00276	CcSEcCtD
Ceftriaxone—Stomatitis—Doxorubicin—muscle cancer	0.0008	0.00275	CcSEcCtD
Ceftriaxone—Jaundice—Doxorubicin—muscle cancer	0.0008	0.00275	CcSEcCtD
Ceftriaxone—Abdominal pain—Etoposide—muscle cancer	0.000797	0.00274	CcSEcCtD
Ceftriaxone—Body temperature increased—Etoposide—muscle cancer	0.000797	0.00274	CcSEcCtD
Ceftriaxone—Vomiting—Vincristine—muscle cancer	0.000792	0.00272	CcSEcCtD
Ceftriaxone—Rash—Vincristine—muscle cancer	0.000785	0.0027	CcSEcCtD
Ceftriaxone—Dermatitis—Vincristine—muscle cancer	0.000784	0.0027	CcSEcCtD
Ceftriaxone—Haematuria—Doxorubicin—muscle cancer	0.000782	0.00269	CcSEcCtD
Ceftriaxone—Headache—Vincristine—muscle cancer	0.00078	0.00268	CcSEcCtD
Ceftriaxone—Epistaxis—Doxorubicin—muscle cancer	0.000774	0.00266	CcSEcCtD
Ceftriaxone—Agranulocytosis—Doxorubicin—muscle cancer	0.000766	0.00263	CcSEcCtD
Ceftriaxone—Chills—Methotrexate—muscle cancer	0.000763	0.00262	CcSEcCtD
Ceftriaxone—Hypersensitivity—Etoposide—muscle cancer	0.000743	0.00256	CcSEcCtD
Ceftriaxone—Haemoglobin—Doxorubicin—muscle cancer	0.00074	0.00254	CcSEcCtD
Ceftriaxone—Nausea—Vincristine—muscle cancer	0.00074	0.00254	CcSEcCtD
Ceftriaxone—Haemorrhage—Doxorubicin—muscle cancer	0.000736	0.00253	CcSEcCtD
Ceftriaxone—Dysgeusia—Methotrexate—muscle cancer	0.000725	0.00249	CcSEcCtD
Ceftriaxone—Pruritus—Etoposide—muscle cancer	0.000714	0.00245	CcSEcCtD
Ceftriaxone—Erythema multiforme—Doxorubicin—muscle cancer	0.000696	0.00239	CcSEcCtD
Ceftriaxone—Diarrhoea—Etoposide—muscle cancer	0.00069	0.00237	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Methotrexate—muscle cancer	0.000687	0.00236	CcSEcCtD
Ceftriaxone—Anaemia—Methotrexate—muscle cancer	0.000684	0.00235	CcSEcCtD
Ceftriaxone—Flushing—Doxorubicin—muscle cancer	0.000684	0.00235	CcSEcCtD
Ceftriaxone—GLUL—embryo—muscle cancer	0.000672	0.107	CbGeAlD
Ceftriaxone—Malaise—Methotrexate—muscle cancer	0.000668	0.0023	CcSEcCtD
Ceftriaxone—Dizziness—Etoposide—muscle cancer	0.000667	0.00229	CcSEcCtD
Ceftriaxone—Leukopenia—Methotrexate—muscle cancer	0.000663	0.00228	CcSEcCtD
Ceftriaxone—Chills—Doxorubicin—muscle cancer	0.000661	0.00227	CcSEcCtD
Ceftriaxone—Convulsion—Methotrexate—muscle cancer	0.000642	0.00221	CcSEcCtD
Ceftriaxone—Vomiting—Etoposide—muscle cancer	0.000641	0.00221	CcSEcCtD
Ceftriaxone—Rash—Etoposide—muscle cancer	0.000636	0.00219	CcSEcCtD
Ceftriaxone—Dermatitis—Etoposide—muscle cancer	0.000635	0.00218	CcSEcCtD
Ceftriaxone—Headache—Etoposide—muscle cancer	0.000632	0.00217	CcSEcCtD
Ceftriaxone—Flatulence—Doxorubicin—muscle cancer	0.000632	0.00217	CcSEcCtD
Ceftriaxone—Dysgeusia—Doxorubicin—muscle cancer	0.000628	0.00216	CcSEcCtD
Ceftriaxone—Discomfort—Methotrexate—muscle cancer	0.000623	0.00214	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Methotrexate—muscle cancer	0.000604	0.00208	CcSEcCtD
Ceftriaxone—Infection—Methotrexate—muscle cancer	0.0006	0.00206	CcSEcCtD
Ceftriaxone—Nausea—Etoposide—muscle cancer	0.000599	0.00206	CcSEcCtD
Ceftriaxone—Ill-defined disorder—Doxorubicin—muscle cancer	0.000595	0.00205	CcSEcCtD
Ceftriaxone—Anaemia—Doxorubicin—muscle cancer	0.000593	0.00204	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Methotrexate—muscle cancer	0.000592	0.00203	CcSEcCtD
Ceftriaxone—Agitation—Doxorubicin—muscle cancer	0.000589	0.00203	CcSEcCtD
Ceftriaxone—Hyperhidrosis—Methotrexate—muscle cancer	0.000584	0.00201	CcSEcCtD
Ceftriaxone—Malaise—Doxorubicin—muscle cancer	0.000578	0.00199	CcSEcCtD
Ceftriaxone—Leukopenia—Doxorubicin—muscle cancer	0.000574	0.00197	CcSEcCtD
Ceftriaxone—Palpitations—Doxorubicin—muscle cancer	0.000567	0.00195	CcSEcCtD
Ceftriaxone—Convulsion—Doxorubicin—muscle cancer	0.000555	0.00191	CcSEcCtD
Ceftriaxone—Paraesthesia—Methotrexate—muscle cancer	0.000543	0.00187	CcSEcCtD
Ceftriaxone—Discomfort—Doxorubicin—muscle cancer	0.000539	0.00185	CcSEcCtD
Ceftriaxone—SLC22A11—renal system—muscle cancer	0.000536	0.0852	CbGeAlD
Ceftriaxone—Dyspepsia—Methotrexate—muscle cancer	0.000532	0.00183	CcSEcCtD
Ceftriaxone—GLUL—smooth muscle tissue—muscle cancer	0.000528	0.0839	CbGeAlD
Ceftriaxone—Oedema—Doxorubicin—muscle cancer	0.000523	0.0018	CcSEcCtD
Ceftriaxone—Anaphylactic shock—Doxorubicin—muscle cancer	0.000523	0.0018	CcSEcCtD
Ceftriaxone—Infection—Doxorubicin—muscle cancer	0.00052	0.00179	CcSEcCtD
Ceftriaxone—Pain—Methotrexate—muscle cancer	0.000517	0.00178	CcSEcCtD
Ceftriaxone—Thrombocytopenia—Doxorubicin—muscle cancer	0.000512	0.00176	CcSEcCtD
Ceftriaxone—GLUL—renal system—muscle cancer	0.000509	0.0808	CbGeAlD
Ceftriaxone—Hyperhidrosis—Doxorubicin—muscle cancer	0.000506	0.00174	CcSEcCtD
Ceftriaxone—Feeling abnormal—Methotrexate—muscle cancer	0.000498	0.00171	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Methotrexate—muscle cancer	0.000494	0.0017	CcSEcCtD
Ceftriaxone—Urticaria—Methotrexate—muscle cancer	0.00048	0.00165	CcSEcCtD
Ceftriaxone—Body temperature increased—Methotrexate—muscle cancer	0.000478	0.00164	CcSEcCtD
Ceftriaxone—Abdominal pain—Methotrexate—muscle cancer	0.000478	0.00164	CcSEcCtD
Ceftriaxone—Paraesthesia—Doxorubicin—muscle cancer	0.00047	0.00162	CcSEcCtD
Ceftriaxone—Dyspepsia—Doxorubicin—muscle cancer	0.000461	0.00158	CcSEcCtD
Ceftriaxone—Pain—Doxorubicin—muscle cancer	0.000447	0.00154	CcSEcCtD
Ceftriaxone—Hypersensitivity—Methotrexate—muscle cancer	0.000445	0.00153	CcSEcCtD
Ceftriaxone—Feeling abnormal—Doxorubicin—muscle cancer	0.000431	0.00148	CcSEcCtD
Ceftriaxone—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000428	0.00147	CcSEcCtD
Ceftriaxone—Pruritus—Methotrexate—muscle cancer	0.000428	0.00147	CcSEcCtD
Ceftriaxone—SLC15A1—renal system—muscle cancer	0.00042	0.0668	CbGeAlD
Ceftriaxone—Urticaria—Doxorubicin—muscle cancer	0.000416	0.00143	CcSEcCtD
Ceftriaxone—Abdominal pain—Doxorubicin—muscle cancer	0.000414	0.00142	CcSEcCtD
Ceftriaxone—Body temperature increased—Doxorubicin—muscle cancer	0.000414	0.00142	CcSEcCtD
Ceftriaxone—Diarrhoea—Methotrexate—muscle cancer	0.000413	0.00142	CcSEcCtD
Ceftriaxone—Dizziness—Methotrexate—muscle cancer	0.0004	0.00137	CcSEcCtD
Ceftriaxone—GLUL—tendon—muscle cancer	0.000397	0.0631	CbGeAlD
Ceftriaxone—Hypersensitivity—Doxorubicin—muscle cancer	0.000386	0.00133	CcSEcCtD
Ceftriaxone—GLUL—bone marrow—muscle cancer	0.000385	0.0611	CbGeAlD
Ceftriaxone—Vomiting—Methotrexate—muscle cancer	0.000384	0.00132	CcSEcCtD
Ceftriaxone—Rash—Methotrexate—muscle cancer	0.000381	0.00131	CcSEcCtD
Ceftriaxone—Dermatitis—Methotrexate—muscle cancer	0.000381	0.00131	CcSEcCtD
Ceftriaxone—Headache—Methotrexate—muscle cancer	0.000379	0.0013	CcSEcCtD
Ceftriaxone—Pruritus—Doxorubicin—muscle cancer	0.00037	0.00127	CcSEcCtD
Ceftriaxone—GLUL—vagina—muscle cancer	0.000368	0.0585	CbGeAlD
Ceftriaxone—Nausea—Methotrexate—muscle cancer	0.000359	0.00123	CcSEcCtD
Ceftriaxone—Diarrhoea—Doxorubicin—muscle cancer	0.000358	0.00123	CcSEcCtD
Ceftriaxone—Dizziness—Doxorubicin—muscle cancer	0.000346	0.00119	CcSEcCtD
Ceftriaxone—GLUL—head—muscle cancer	0.00034	0.0541	CbGeAlD
Ceftriaxone—Vomiting—Doxorubicin—muscle cancer	0.000333	0.00114	CcSEcCtD
Ceftriaxone—Rash—Doxorubicin—muscle cancer	0.00033	0.00113	CcSEcCtD
Ceftriaxone—Dermatitis—Doxorubicin—muscle cancer	0.00033	0.00113	CcSEcCtD
Ceftriaxone—GLUL—testis—muscle cancer	0.000329	0.0522	CbGeAlD
Ceftriaxone—Headache—Doxorubicin—muscle cancer	0.000328	0.00113	CcSEcCtD
Ceftriaxone—Nausea—Doxorubicin—muscle cancer	0.000311	0.00107	CcSEcCtD
Ceftriaxone—SLC15A1—vagina—muscle cancer	0.000305	0.0484	CbGeAlD
Ceftriaxone—SLC22A8—renal system—muscle cancer	0.000302	0.048	CbGeAlD
Ceftriaxone—SLC15A2—renal system—muscle cancer	0.000263	0.0417	CbGeAlD
Ceftriaxone—ALB—testis—muscle cancer	0.000204	0.0323	CbGeAlD
Ceftriaxone—SLC22A8—head—muscle cancer	0.000202	0.0321	CbGeAlD
Ceftriaxone—SLC15A2—vagina—muscle cancer	0.00019	0.0302	CbGeAlD
Ceftriaxone—SLC15A2—head—muscle cancer	0.000176	0.0279	CbGeAlD
Ceftriaxone—SLC15A2—testis—muscle cancer	0.00017	0.027	CbGeAlD
